Please login to the form below

Not currently logged in
Email:
Password:

antibody drug conjugate

This page shows the latest antibody drug conjugate news and features for those working in and with pharma, biotech and healthcare.

AbbVie slumps on trial results for would-be blockbuster Rova-T

AbbVie slumps on trial results for would-be blockbuster Rova-T

The fall-off is no surprise given that AbbVie has spent the last few months building up expectations for antibody-drug conjugate Rova-T (rovalpituzumab tesirine), pointing to its blockbuster sales ... Rova-T comprises an anti-DLL3 antibody linked to a

Latest news

  • Seattle Genetics claims key US approval for Adcetris Seattle Genetics claims key US approval for Adcetris

    Adcetris (brentuximab vedotin), an antibody-drug conjugate, is the first new treatment for this type of lymphoma in more than 40 years, with the US regulator approving it for use alongside ... Crucially, Adcetris avoids the use of the chemotherapy drug

  • Pfizer’s leukaemia drug Mylotarg backed for use in EU Pfizer’s leukaemia drug Mylotarg backed for use in EU

    Pfizer’ s leukaemia drug Mylotarg backed for use in EU. The CHMP’s positive opinion could see the drug return to market after almost eight years. ... Mylotarg (gemtuzumab ozogamicin) was the first antibody-drug conjugate to reach the market nearly

  • Takeda bags EU approval for Adcetris in lymphoma Takeda bags EU approval for Adcetris in lymphoma

    Takeda bags EU approval for Adcetris in lymphoma. Data shows the drug improves PFS and symptom burden in CTCL patients. ... CTCL). Adcetris (brentuximab vedotin) - a CD30-targeting antibody drug conjugate (ADC) - already has conditional approval in the

  • Seattle Genetics' Adcetris earns FDA priority review status Seattle Genetics' Adcetris earns FDA priority review status

    Seattle Genetics’Adcetris has received a boost after the US Food and Drug Administration’s (FDA) granted the lymphoma drug priority review status. ... Adcetris (brentuximab vedotin), an antibody-drug conjugate, was awarded the status based on the

  • NICE reverses stance on Takeda’s Adcetris NICE reverses stance on Takeda’s Adcetris

    NICE reverses stance on Takeda’ s Adcetris. But firm criticises final draft guidance's new restrictions on the non-Hodgkin’s lymphoma drug. ... The antibody-drug conjugate is now set to be backed to treat relapsed or refractory (R/R) systemic

More from news
Approximately 2 fully matching, plus 54 partially matching documents found.

Latest Intelligence

  • Deal Watch January 2018

    used to progress the clinical development of the company's immuno-oncology antibody therapeutics against the checkpoint targets CTLA-4 and PD-1. ... Also in January Immunomedics sold tiered royalty rights on global net sales of its antibody drug conjugate

  • Pharma deals continue to slide Pharma deals continue to slide

    Roche has licensed a monoclonal antibody in phase II to Dermira, a dermatology company. ... 250+. Immunogen (US). Jazz (IE, US). Collaboration and option. Phase I haematology-related antibody-drug conjugate plus 2 other projects.

  • Deal Watch February 2017 Deal Watch February 2017

    Competitive deal tendering and investor revolt. One of the largest therapeutic deals in February was the Immunomedics licence with Seattle Genetics for a phase 2 stage antibody drug conjugate (ADC), sacituzumab ... Acquisition - company. 2, 475.

  • Deal Watch April 2016 Deal Watch April 2016

    Its lead compound, Rovalpituzumab tesirine (Rova-T), is a biomarker-specific antibody drug conjugate, in phase I/II targeting cancer stem cell protein DLL3. ... Phase I antibody drug conjugate targeting cancer stem cell protein DLL3.

  • Deal Watch January 2016 Deal Watch January 2016

    363. Complix/ Merck &Co. Collaboration. Drug discovery collaboration to develop Cell-Penetrating Alphabodies (CPABs) for the treatment of cancer. ... Abzena/(Partner nd). Licence . Novel site specific ThioBridge antibody drug conjugate (ADC) linker

More from intelligence
Approximately 0 fully matching, plus 15 partially matching documents found.

Latest appointments

  • Glythera strengthens its scientific advisory board and appoints CSO Glythera strengthens its scientific advisory board and appoints CSO

    Glythera has appointed new chief scientific officer Dr Robert Lutz to lead the advancement of the UK-based biotech's antibody drug conjugate portfolio.

  • Glythera appoints Dr Mike Owen Glythera appoints Dr Mike Owen

    Antibody drug conjugate development company, Glythera has appointed Dr Mike Owen as its non-executive director. ... At GSK, Owen was responsible for initiating and growing the group’s pre-clinical and clinical therapeutic antibody pipeline through

  • ADC Therapeutics expands team ADC Therapeutics expands team

    ADC Therapeutics expands team. Appointments preceed its first antibody drug conjugate trials. ... ADC Therapeutics has significantly expanded its team head of putting its first antibody drug conjugates (ADCs) into clinical development.

More from appointments
Approximately 0 fully matching, plus 3 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
wethepeople

wethepeople are bringing human appeal back to brand communications. Our approach allows us to create strategies, ideas and experiences that...

Latest intelligence

Developing advocacy in the pharmaceutical industry.
The importance of advocacy programmes...
GDPR and events. What does the pharma industry need to know?
...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....

Infographics